Sruti Prathivadhi-Bhayankaram

Sruti Prathivadhi-Bhayankaram


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 August 2020 in Life
Verified
Journal Article
Open access
PDF file
DPDevika Prasanth
Devika Prasanth
SSSindhuja Suresh
Sindhuja Suresh
SPSruti Prathivadhi-Bhayankaram
Sruti Prathivadhi-Bhayankaram
MMMichael Mimlitz
Michael Mimlitz
NZNoah Zetocha
Noah Zetocha
Andrew EkpenyongAndrew Ekpenyong
Andrew Ekpenyong
Microgravity or the condition of apparent weightlessness causes bone, muscular and immune system dysfunctions in astronauts following spaceflights. These organ and system-level dysfunctions correlate with changes induced at the single cell level both by simulated microgravity on earth as well as microgravity conditions in outer space (as in the international space station). Reported changes in single bone cells, muscle cells and white blood cells include structural/morphological abnormalities, changes in gene expression, protein expression, metabolic pathways and signaling pathways, suggesting that cells mount some response or adjustment to microgravity. However, the implications of such adjustments on many cellular functions and responses are not clear largely because the primary mechanism of gravity sensing in animal cells is unknown. Here, we used a rotary cell culture system developed by NASA to subject leukemic and erythroleukemic cancer cells to microgravity for 48 h and then quantified their innate immune response to common anti-cancer drugs using biophysical parameters and our recently developed quantum-dot-based fluorescence spectroscopy. We found that leukemic cancer cells treated with daunorubicin show increased chemotactic migration (p < 0.01) following simulated microgravity (µg) compared to normal gravity on earth (1 g). However, cells treated with doxorubicin showed enhanced migration both in 1 g and following µg. Our results show that microgravity modulates cancer cell response to chemotherapy in a drug-dependent manner. These results suggest using simulated microgravity as an immunomodulatory tool for the development of new immunotherapies for both space and terrestrial medicine.

25 February 2022 in Preprints.org
Verified
Preprint
Open access
PDF file
MAMarcus Inyama Asuquo
Marcus Inyama Asuquo
EEEmmanuel Effa
Emmanuel Effa
OGOluwabukola Gbotosho
Oluwabukola Gbotosho
AOAkaninyene Otu
Akaninyene Otu
NTNicole Toepfner
Nicole Toepfner
Andrew EkpenyongAndrew Ekpenyong
Andrew Ekpenyong
Sickle cell disorder (SCD) is a multisystem disease with heterogeneous phenotypes. Although all patients have the mutated haemoglobin (Hb) in the SS phenotype, the severity and frequency of complications are variable. When exposed to low oxygen tension, the Hb molecule becomes dense and, forms tactoids which, lead to the peculiar sickled shapes of the affected red blood cells, giving the disorder its name. This sickle cell morphology is responsible for the profound and widespread pathologies associated with this disorder, such as vaso-occlusive crisis, (VOC). How much of the clinical manifestation is due to sickled erythrocytes and what is due to the relative contributions of other elements in the blood, especially in the microcapillary circulation, is usually not visualized and quantified for each patient during clinical management. Here, we used a microfluidic microcirculation mimetic (MMM) which has 187 capillary-like constrictions to impose deformations on erythrocytes of SCD patients, visualizing and characterizing the morpho-rheological properties of the cells in normoxic, hypoxic (using of sodium meta-bisulfite) and in treatment conditions (using hydroxyurea). The MMM enabled a patient-specific quantification of shape descriptors (circularity and roundness) and transit time through the capillary constrictions, which are readouts for morphorheological properties implicated in VOC. Our results demonstrate the feasibility of microfluidics-based monitoring of individual patients for personalized care in the context of SCD complications such as VOC, even in re-source-challenged settings.

30 December 2019 in bioRxiv
Verified
Preprint
Open access
PDF file
DPDevika Prasanth
Devika Prasanth
SSSindhuja Suresh
Sindhuja Suresh
SPSruti Prathivadhi-Bhayankaram
Sruti Prathivadhi-Bhayankaram
MMMichael Mimlitz
Michael Mimlitz
NZNoah Zetocha
Noah Zetocha
Andrew EkpenyongAndrew Ekpenyong
Andrew Ekpenyong
Microgravity or the condition of apparent weightlessness causes bone, muscular and immune system dysfunctions in astronauts following spaceflights. These organ and system-level dysfunctions correlate with changes induced at the single cell level both by simulated microgravity on earth as well as microgravity conditions in outer space (as in the international space station). Reported changes in single bone cells, muscle cells and white blood cells include structural/morphological abnormalities, changes in gene expression, protein expression, metabolic pathways and signaling pathways, suggesting that cells mount some response or adjustment to microgravity. However, the implications of such adjustments on many cellular functions and responses are not clear largely because the primary mechanism of gravity sensing in animal cells is unknown. Here we used a rotary cell culture system developed by NASA, to subject leukemic and erythroleukemic cancer cells to microgravity for 48 hours and then quantified their innate immune-response to common anti-cancer drugs using biophysical parameters and our recently developed quantum-dots-based fluorescence spectroscopy. We found that leukemic cancer cells treated with daunorubicin show increased chemotactic migration (p < 0.01) following simulated microgravity (μg) compared to normal gravity on earth (1g). However, cells treated with doxorubicin showed enhanced migration both in 1g and following μg. Our results show that microgravity modulates cancer cell response to chemotherapy in a drug-dependent manner. These results suggest using simulated microgravity as an immunomodulatory tool for the development of new immunotherapies for both space and terrestrial medicine.